Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VacA is a secreted protein toxin produced by Helicobacter pylori, known as vacuolating cytotoxin A, rather than a conventional pharmaceutical product. It forms anion-selective membrane channels and pores, disrupts endosomal and lysosomal trafficking, perturbs mitochondrial function, and induces cytoplasmic vacuolization and apoptosis in gastric and immune cells, contributing to gastric injury and carcinogenesis in H. pylori infection.[7] VacA also has potent immunomodulatory effects, including inhibition of T‑cell proliferation, reduced B‑cell activation, and promotion of regulatory T cells, which facilitates chronic colonization; because of its central role in H. pylori pathogenesis and strong antigenicity, it has been investigated as a component antigen in experimental H. pylori vaccines.[7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VacA.